Opus Genetics is a gene therapy company for ultra-rare blinding conditions.
Opus Genetics is a patient-first, science-driven gene therapy company tackling manufacturing obstacles standing in the way of treatments for ultra-rare blinding conditions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 22, 2021 | Seed | $19M | 1 | Retinal Degeneration Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Retinal Degeneration Fund | Yes | Seed |